Topic: Takeda Pharmaceutical Co. Ltd.

New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone

Drugs.com - 844 days ago
A study, published online in the journal Current Medical and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of ...

Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and Actos (pioglitazone HCl) for the Treatment of Type 2 Diabetes

Drugs.com - 881 days ago
Takeda") today announced that its wholly owned subsidiary, Takeda Global & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose ...

Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes

Drugs.com - 891 days ago
Takeda") and Takeda Global & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) ...

SYR-322/Actos

Drugs.com - 927 days ago
Takeda") today announced that Takeda Global & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification from the U.S. Food and Drug Administration (FDA) that the FDA extended the review of the New Drug Application (NDA) for the fixed-dose ...

FDA Approves ACTOplus met XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes

Drugs.com - 994 days ago
First and only oral antidiabetic fixed-dose combination medication approved with the extended-release form of metformin. Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved an extended-release version ...

Interesting New Data on the Effect of Candesartan on Diabetic Eye Complications

Drugs.com - 1242 days ago
OSAKA, Japan, --Data from the DIRECT Programme, the first large-scale study programme assessing the effect of treatment with an angiotensin receptor blocker (ARB) on the incidence and progression of diabetic eye complications, was presented today at the European Association of the Study ...

New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with Actos (pioglitazone HCl)

Drugs.com - 1391 days ago
Additional results from the clinical trial CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne) published today in Circulation revealed that reduced progression of carotid intima-media thickness (CIMT) with ACTOS(R) (pioglitazone HCl) was associated with increased levels of HDL cholesterol (HDL-C, or " ...